The present invention relates generally to appetite regulation, and specifically to invasive techniques and apparatus for appetite control and treating obesity.
Morbid obesity is a difficult to treat chronic condition defined by a body mass index (BMI=mass/height2[kg/m2]) greater than 40. For obese persons, excessive weight is commonly associated with increased risk of cardiovascular disease, diabetes, degenerative arthritis, endocrine and pulmonary abnormalities, gallbladder disease and hypertension. Additionally, such persons are highly likely to experience psychological difficulties because of lifestyle restrictions such as reduced mobility and physical capacity, due to back pain, joint problems, and shortness of breath. In severe cases, this can contribute to absenteeism and unemployment. Moreover, impairment of body image can lead to significant psychological disturbances. Repeated failures of dieting and exercise to resolve the problem of obesity can result in feelings of despair and the development of clinical depression.
Bariatric surgery is often recommended for persons suffering from morbid obesity. Preferably, the invasive treatment is accompanied by changes in lifestyle, such as improved regulation of eating habits and an appropriate exercise regimen. Such lifestyle changes are dependent upon the self-discipline and cooperation of the patient.
A book entitled, Textbook of Gastroenterology, 3rd edition, edited by Yamada (Lippincott, Williams & Wilkns), which is incorporated herein by reference, has in Chapter 10 thereof, a description of the physiology of gastric motility and gastric emptying.
An abstract entitled, “Gastric myoelectrical pacing as therapy for morbid obesity: Preliminary results,” by Cigaina et al., retrieved on Dec. 24, 2000 from the Web-site http://www.med-online.com/transneuronix/Product/abstract.htm, which is incorporated herein by reference, describes a method for applying monopolar and bipolar gastric stimulation to achieve weight loss.
An abstract entitled, “Implantable gastric stimulator (IGS) as therapy for morbid obesity: Equipment, surgical technique and stimulation parameters,” by Cigaina et al., retrieved on Dec. 24, 2000 from the Web-site http://www.med-online.com/transneuronix/Product/abstract.htm, which is incorporated herein by reference, describes techniques of electrical signal therapy designed to treat obesity.
U.S. Pat. No. 6,129,685 to Howard, which is incorporated herein by reference, describes apparatus and methods for regulating appetite by electrical stimulation of the hypothalamus and by microinfusion of an appropriate quantity of a suitable drug to a distinct site or region within the hypothalamus.
U.S. Pat. No. 4,823,808 to Clegg et al., which is incorporated herein by reference, describes a method for treating obesity, including receiving a physiological measurement and generating audio and/or visual feedback for the patient to hear and/or see. The feedback is used for purposes of teaching behavior modification.
U.S. Pat. No. 5,868,141 to Ellias, which is incorporated herein by reference, describes an endoscopic stomach insert for reducing a patient's desire to eat.
U.S. Pat. No. 6,067,991 to Forsell, U.S. Pat. No. 5,601,604 to Vincent, U.S. Pat. No. 5,234,454 to Bangs, U.S. Pat. No. 4,133,315 to Berman et al., U.S. Pat. No. 4,416,267 to Garren et al., and U.S. Pat. Nos. 4,592,339, 5,449,368, 5,226,429 and 5,074,868 to Kuzmak, which are incorporated herein by reference, describe mechanical instruments for implantation in or around the stomach of an obese patient.
U.S. Pat. No. 5,690,691 to Chen et al., which is incorporated herein by reference, describes a gastric pacemaker for treating obesity and other disorders. The pacemaker includes multiple electrodes which are placed at various positions on the gastrointestinal (GI) tract, and deliver phased electrical stimulation to pace peristaltic movement of material through the GI tract.
U.S. Pat. No. 5,423,872 to Cigaina, which is incorporated herein by reference, describes apparatus for applying electrical pulses to the distal gastric antrum of a patient, so as to reduce the motility of the stomach and to thereby treat obesity or another disorder.
U.S. Pat. Nos. 5,188,104 and 5,263,480 to Wernicke et al., which are incorporated herein by reference, describe a method for stimulating the vagus nerve of a patient so as to alleviate an eating disorder.
U.S. Pat. Nos. 6,104,955, 6,091,992, and 5,836,994 to Bourgeois, U.S. Pat. No. 6,026,326 to Bardy, and U.S. Pat. No. 3,411,507 to Wingrove, which are incorporated herein by reference, describe the application of electrical signals to the GI tract to treat various physiological disorders.
U.S. Pat. No. 5,979,449 to Steer, which is incorporated herein by reference, describes an oral appliance for appetite suppression.
U.S. Pat. No. 4,975,682 to Kerr et al., which is incorporated herein by reference, describes apparatus for food intake regulation which is external to the body and which is based upon the voluntary cooperation of the subject in order to be effective.
U.S. Pat. Nos. 5,861,014, 5,716,385 and 5,995,872 are incorporated herein by reference, and describe methods and apparatus for stimulation of tissue, particularly gastrointestinal tract tissue.
PCT Patent Publication WO 98/10830 to Ben-Haim et al., entitled, “Fencing of cardiac muscles,” and U.S. patent application Ser. No. 09/254,903 in the national phase thereof, both of which are assigned to the assignee of the present patent application and are incorporated herein by reference, describe various methods for controlling the behavior of muscle tissue, for example by blocking or altering the transmission of signals therethrough.
PCT Patent Publication WO 99/03533 to Ben-Haim et al., entitled, “Smooth muscle controller,” and U.S. patent application Ser. No. 09/481,253 in the national phase thereof, both of which are assigned to the assignee of the present patent application and are incorporated herein by reference, describe apparatus and methods for applying signals to smooth muscle so as to modify the behavior thereof. In particular, apparatus for controlling the stomach is described in which a controller applies an electrical field to electrodes on the stomach wall so as to modify the reaction of muscle tissue therein to an activation signal, while not generating a propagating action potential in the tissue. In the context of the present patent application and in the claims, the use of such a non-excitatory signal to modify the response of one or more cells to electrical activation thereof, without inducing action potentials in the cells, is referred to as Excitable-Tissue Control (ETC). Use of an ETC signal is described with respect to treating obesity, by applying the ETC signal to the stomach so as to delay or prevent emptying of the stomach. In addition, a method is described for increasing the motility of the gastrointestinal tract, by applying an ETC signal to a portion of the tract in order to increase the contraction force generated in the portion and the stretching of nearby tissue.
It is an object of some aspects of the present invention to provide apparatus and methods for regulation of appetite and food ingestion.
It is a further object of some aspects of the present invention to provide improved apparatus and methods for treating obesity.
It is yet a further object of some aspects of the present invention to provide apparatus and methods that enable change in food ingestion habits in a predictable and controlled manner.
It is still a further object of some aspects of the present invention to provide apparatus and methods for bariatric surgery which are less drastic than those currently employed.
In preferred embodiments of the present invention, apparatus for regulating a patient's food ingestion comprises a sensor which detects: (a) the patient swallowing, (b) the filling of the patient's stomach, and/or (c) the onset of contractions in the stomach as a result of eating. Preferably, a timing module stores in an electronic memory the time of each swallow and/or meal. Additionally or alternatively, a measuring module stores in the memory the amount of food consumed in the meal. Further additionally or alternatively, the measuring module determines a quality of the food, for example whether it is predominantly solid or liquid. For most applications, a specific schedule of allowed food ingestion is pre-programmed by a physician into the memory, and a processor is continuously operative to detect whether food consumption is taking place in accordance with the programmed schedule. For some patients, the schedule may be less strict with respect to the drinking of liquids, and more strict with respect to the eating of solid food. When an exception from the schedule is detected, the processor actuates a signal generator to convey an ingestion-control signal to the patient, in order to encourage the patient to adhere to the schedule.
Typically, the ingestion-control signal is delivered to the patient's stomach via a set of electrodes placed in a vicinity thereof, so as to induce a sensation of satiety, discomfort, or minor nausea Thus, for example, in response to detecting a violation of the patient's prescribed diet and/or eating schedule, the processor may drive the signal generator to induce an unpleasant sensation (e.g., nausea) by altering the natural electrical activity of the stomach, thereby inducing gastric dysrhythmia. For some applications, the signal is applied to another site on or in the patient's body. For example, the ingestion-control signal may be applied mechanically or electrically in a vicinity of the cochlear nerve, so as to induce vertigo. Alternatively or additionally, the signal is applied so as to generate a brief pain sensation anywhere on the patient's body, which only recurs if the patient continues to eat.
Preferably, but not necessarily, the measuring module determines the quality of the food (e.g., solid or liquid) by interpreting electrical signals generated in the gastrointestinal tract. Further preferably, the measuring module makes the determination using techniques described in the above-cited Textbook of Gastroenterology, Volume II, Chapter 10, which is incorporated herein by reference. Alternatively or additionally, the determination may be made using chemical means (e.g., a pH sensor) or mechanical sensors.
For some applications, a signal is applied to the esophagus or to the lower esophageal sphincter, so as to cause contraction of muscle tissue therein, thereby making any further eating difficult or uncomfortable.
Alternatively or additionally, the ingestion-control signal is configured so as to induce a feeling of satiation, preferably but not necessarily using methods or apparatus described in U.S. patent application Ser. No. 09/734,358, entitled, “Acute and chronic electrical signal therapy for obesity,” filed Dec. 11, 2000, or in U.S. Provisional Patent Application No. 60/259,925, entitled, “Regulation of eating habits,” filed Jan. 5, 2001, both of which are assigned to the assignee of the present patent application and incorporated herein by reference. For example, methods described in those applications for engendering a feeling of satiation may be applied in conjunction with embodiments of the present invention, such that muscles in the vicinity of stretch receptors in the stomach are caused to contract, thereby resulting in decreased hunger sensations. Alternatively or additionally, the feeling of satiation is induced by applying electrical signals which enhance the mobility of chyme from the fundus to the antru=of the stomach, where stretch-receptor signals are generally generated to a greater extent for a given quantity of food than in the fundus.
Preferably, the schedule of allowed food ingestion can be modified after implantation of the apparatus, typically by means of a wireless communications link. In this manner, the schedule can be adjusted in response to changes in the patient's eating habits and experience with the apparatus.
There is therefore provided, in accordance with a preferred embodiment of the present invention, a method for treating a subject, including:
receiving a sensor signal responsive to the subject eating;
analyzing the sensor signal; and
driving a current into tissue of the subject responsive to analyzing the signal.
Typically, receiving the sensor signal includes sensing an electrical potential change generated responsive to contraction of a muscle of the subject. In addition, analyzing the sensor signal may include identifying a change in a measure of electrical impedance between two sites of the muscle. Alternatively or additionally, analyzing the sensor signal may include identifying a change in a frequency component of the electrical potential, e.g., a frequency component which is in the range of approximately 2-7 cycles per minute.
For some applications, receiving the sensor signal includes measuring a change in a physical disposition of a muscle of the subject, or measuring a change in a chemical constituent of the subject.
In a preferred embodiment, receiving the sensor signal includes receiving a signal generated in response to a measurement made at an esophageal site of the subject. Alternatively or additionally, receiving the sensor signal includes receiving a signal generated in response to a measurement made in a vicinity of a stomach of the subject For some applications, receiving the sensor signal includes measuring swallowing of the subject.
In a preferred embodiment, driving the current includes driving a current into aural tissue of the subject.
Typically, driving the current includes driving a current into tissue of a gastrointestinal tract of the subject, e.g., into tissue of a stomach of the subject For example, driving the current may include driving the current into a cardiac site of the stomach, a fundic site of the stomach, a site in a body of the stomach, a distal site of the stomach, a pyloric site of the stomach, and/or an antral site of the stomach. A “cardiac site of the stomach” refers to a site in close proximity to the esophageal opening of the stomach.
For some applications, receiving the sensor signal includes measuring an indication of a quantity of ingesta ingested by the subject, and analyzing the sensor signal includes analyzing the sensor signal responsive to the quantity.
Alternatively or additionally, analyzing the sensor signal includes analyzing the sensor signal responsive to a time of ingestion. For example, analyzing the sensor signal responsive to the time of ingestion may include determining a level of compliance of the subject with an ingestion schedule. Determining the level of compliance typically includes counting a number of meals consumed by the subject during a designated time period, and/or counting a number of times that the subject swallows food. If appropriate, analyzing the sensor signal may additionally include receiving a modification to the ingestion schedule, and analyzing the sensor signal responsive to the modified ingestion schedule. In this latter case, receiving the modification to the ingestion schedule preferably includes receiving the modification by wireless communication from a source outside of the body of the subject.
Driving the current preferably includes applying an Excitable-Tissue Control (ETC) signal to the tissue, applying a fencing signal to the tissue, and/or applying excitatory pulses to the tissue. In a preferred embodiment, the method includes applying a stimulatory pulse at a site of application of the ETC signal. Alternatively or additionally, the method includes applying a stimulatory pulse to tissue at a site other than a site of application of the ETC signal.
For some applications, applying the ETC signal includes detecting natural gastric electrical activity and applying the ETC signal responsive thereto. For example, detecting the natural gastric electrical activity may include detecting the natural gastric electrical activity at a gastric site, and applying the ETC signal may include applying the ETC signal at the same gastric site. Alternatively or additionally, detecting the natural gastric electrical activity includes detecting at a first site, and applying the ETC signal includes applying the ETC signal at a second site, different from the first site. In this latter case, applying the ETC signal at the second site preferably includes timing the application of the ETC signal at the second site responsive to a distance between the first and second sites.
For some applications, driving the current includes:
driving the current into muscle tissue of the subject; and
configuring a parameter of the current such that application of the current to the muscle tissue causes an increase in an aspect of contraction of the muscle tissue.
In this case, driving the current typically includes driving the current into muscle tissue of a stomach of the subject, and configuring the parameter includes configuring the parameter such that application of the current to the stomach muscle tissue causes tissue contraction in a first portion of the stomach, and, in conjunction with the subject eating, stretching of a stretch receptor of the stomach in a second portion of the stomach. Alternatively or additionally, driving the current includes driving the current into muscle tissue of a stomach of the subject, and configuring the parameter includes configuring the parameter such that application of the current to the stomach muscle tissue enhances movement of chyme from a fundus to an antrum of the stomach.
Configuring the parameter typically includes configuring the parameter such that application of the current to the muscle tissue induces a sensation of satiation, discomfort, nausea, and/or vertigo of the subject. Alternatively or additionally, driving the current includes configuring a parameter of the current such that application of the current causes gastric dysrhytmia of the subject. Further alternatively or additionally, driving the current includes configuring a parameter of the current such that application of the current disrupts coupling of gastric mechanical activity and gastric electrical activity of the subject.
There is also provided, in accordance with a preferred embodiment of the present invention, apparatus for treating a subject, including:
at least one sensor, adapted to generate a sensor signal responsive to the subject eating;
a set of one or more electrodes, adapted to be coupled to tissue of the subject; and
a control unit, adapted to receive the sensor signal, and to drive a current, responsive to analysis of the signal, through the set of electrodes into the tissue.
Preferably, the sensor includes at least one of the electrodes. Alternatively or additionally, the sensor includes a mechanical sensor or at least one sensing electrode. In a preferred embodiment, the sensor includes two sensing electrodes, adapted to be coupled to respective sites of the tissue, and the control unit is adapted to identify a change in a measure of electrical impedance between two sites of the tissue, and to drive the current responsive to identifying the change. Alternatively or additionally, the control unit is adapted to identify a change in a frequency component of a sensed current flowing through the sensing electrode, and to drive a driving current through the set of electrodes responsive to identifying the change in the frequency component of the sensed current.
In a preferred embodiment, the control unit includes a memory, adapted to store an ingestion schedule, and the control unit is adapted to withhold driving the current when the sensor signal is indicative of the subject eating in accordance with the ingestion schedule.
For some applications, the apparatus includes an operator unit, which is adapted to be placed external to the subject and to transmit a control signal to the control unit, wherein the control unit is adapted to analyze the sensor signal responsive to the control signal and to drive the current responsive to analyzing the sensor signal.
The present invention will be more fully understood from the following detailed description of the preferred embodiments thereof, taken together with the drawings, in which:
Electrodes 100 are typically coupled to the serosal layer of the stomach and/or inserted into the muscular layer of the stomach. Alternatively or additionally, the electrodes are coupled elsewhere on the stomach, gastrointestinal tract, or to other suitable locations in or on the patient's body. The number of electrodes and sensors, as well as the positions thereof, are shown in
Preferably, apparatus 18 is implanted in the patient in a manner generally similar to that used to implant gastric pacemakers or other apparatus for stimulating the gastrointestinal tract which are known in the art. As appropriate, techniques described in one or more of the patents and patent publications cited in the Background section of the present patent application may be adapted for use with these embodiments of the present invention.
Preferably, block 80 determines each time that the patient swallows food, or each time that the patient's stomach begins to contract in response to a threshold level of ingested food. For example, local sense electrodes 74 may send signals indicative of contraction of the esophagus or of the stomach, such that block 80 may process the signals to determine whether eating has occurred. Alternatively or additionally, block 80 may filter and process the output of mechanical sensors 70 situated in the esophagus or in the stomach, so as to identify mechanical activity of the gastrointestinal tract indicative of eating. Further alternatively or additionally, block 80 may process data from supplemental sensors 72 concerning the blood sugar level of the patient, to enable an evaluation of whether food has been ingested. (It is to be understood in the context of the present patent application and in the claims that the terms “food” and “eating” apply equally to “liquids” and “drinking.”)
Block 80 typically conveys results of its analysis of the inputs from mechanical sensors 70, supplemental sensors 72, and local sense electrodes 74, to a “parameter search and tuning” block 84 of control unit 90. Block 84 preferably evaluates the analysis performed by block 80 with respect to a pre-programmed or variable ingestion schedule stored in a memory block 88 of control unit 90, so as to determine whether the patient is in compliance with the schedule. If it is determined that the patient's eating is not in compliance with the schedule (e.g., the patient has eaten too much at one meal, or has eaten too many meals in a day), then block 84 preferably actuates a signal generator block 86 to generate electrical signals that are applied by electrodes 100 to tissue of the patient. Block 86 preferably comprises amplifiers, isolation units, and other standard circuitry known in the art of electrical signal generation.
The signals generated by block 86 are preferably configured so as to induce a response appropriate for controlling the patient's eating habits. For example, block 86 may drive electrodes 100 to apply signals to the stomach which induce gastric dysrhythmia and the resultant feeling of discomfort or nausea. Alternatively or additionally, the signals are applied to an aural site of the patient (e.g., in a vicinity of the cochlear nerve or the tympanic membrane), and are configured to induce vertigo, or another unpleasant balance-related sensation.
For some applications, control unit 90 drives electrodes 100 to apply a modulation signal to muscle in one area of stomach 20, so as to induce a contraction and/or enhance a spontaneous contraction of the stimulated muscle which, in turn induces satiety, e.g., when food in an adjacent area of the stomach causes additional stretching and/or “pinching” (local, high-intensity contraction) of stretch-receptors therein. This signal may be applied in addition to or instead of the signals described hereinabove which produce gastric or other discomfort. The form of contraction-mediated stretching utilized in these applications simulates the normal appetite-reduction action of the stomach's stretch-receptors, without the patient having eaten the quantities of food which would normally be required to trigger tis appetite-reduction response.
Preferably, the signals applied by electrodes 100 include, as appropriate, an Excitable-Tissue Control (ETC) signal and/or an excitatory signal and/or a fencing signal, so as to induce, modulate, enhance, or inhibit contraction of muscles of the stomach. Aspects of ETC signal application are typically performed in accordance with techniques described in the above-referenced PCT Publications WO 99/03533 and WO 97/25098 and their corresponding U.S. national phase application Ser. Nos. 09/481,253 and 09/101,723, mutatis mutandis. It is noted that for many applications, it is advantageous to apply the various types of signals to the stomach in combination, e.g., to apply an ETC signal and pacing pulses intermittently at the same site, or to apply an ETC signal, an excitatory signal, and a fencing signal at different sites of the stomach, in order to induce sensations which are not conducive to further eating. Alternatively or additionally, an ETC signal may be applied to a site on the stomach shortly after an artificial stimulatory (e.g., pacing) pulse is applied at or near the site, and not in response to detected natural gastric electrical activity.
Preferably, regulation apparatus 18 includes remote operator controls 71, external to the patient's body. This remote unit is typically configured to enable the patient or his physician to change parameters of the ingestion schedule stored in memory block 88. For example, if the patient has lost weight, the physician may change the ingestion schedule to allow a single mid-afternoon snack Alternatively or additionally, operator controls 71 comprise an override button, so that the patient may eat outside of the designated meal times, if the need arises. Operator controls 71 preferably communicate with control unit 90 using standard methods known in the art, such as magnetic induction or radio frequency signals.
Pre-programmed parameters utilized by control unit 90 in this illustration include the number of allowed meals per day, the number of swallows that define a meal, and the minimum time duration between meals. The steps in the algorithm are seen to be configured such that if either: (a) the number of swallows per meal exceeds that permitted by the pre-programmed schedule, or (b) the number of meals eaten during a day exceeds the allowed number, then a signal will be applied for a fixed duration to electrodes 100, as described hereinabove. It is noted that in addition to the function described above, the variable “time_between_meals” can be set to a relatively low value, e.g., 30 minutes, and thereby allow the patient to swallow food less frequently than once every 30 minutes without having this increase the swallow_counter variable.
It is to be appreciated that whereas the algorithm shown in
Reference is now made to
In this experiment, baseline pressure data were recorded by a transducer within the balloon, and gastric electrical activity was simultaneously monitored by sense electrodes placed at two sites on the stomach. During this baseline period, the stomach is seen to be relatively quiet, with Electrical Control Activity (ECA) being present, but without any Electrical Response Activity (ERA). After about 4 minutes, the balloon was inflated, thereby inducing a series of gastric contractions, which are detectable directly in the upper graph of
Reference is now made to
The results shown in
It is noted that two ETC signal protocols have been found particularly useful. In the first, sensing of gastric electrical activity at a site is essentially immediately followed by ETC signal application thereto. In the second protocol, sensing is performed at a proximal (upstream) site, and an ETC signal is applied to a distal (downstream) site at the time when it is estimated that the natural gastric electrical activity sensed at the proximal site will have propagated to the distal site. This time delay is calculated by dividing the distance between the sensing and signal-application electrodes by the estimated propagation velocity of the natural gastric electrical activity. In either protocol, it may be suitable to apply an additional delay, after the gastric electrical activity has initiated at a site, before applying the ETC signal thereto.
In the experiment whose results are shown in
It is expected that when analogous stimulation protocols are applied in humans, mutatis mutandis, such a reduction or modification of gastric activity will produce varying levels of discomfort or nausea. It is noted that whereas it is known in the art that when patients experience nausea, there is commonly associated therewith a reduction of gastric electrical activity (particularly a reduction in the rate of slow wave generation), the prior art does not teach the deliberate reduction of gastric activity so as to induce nausea. In other experiments (not shown), it was found that the polarity of the applied fencing signal can be modified so as to affect the response of the muscle tissue.
The results of this experiment clearly demonstrate that application of ETC as described herein generates a gradual but significant weight loss. In particular, during the 34 days of ETC signal application (from day 11 to day 44), the dog showed a maximal weight loss of 7% (1.5 kg from 21 kg). The dog maintained a generally low weight for two weeks, from day 28 to day 43.
It is to be understood that methods and apparatus described hereinabove may be used advantageously in combination with drug treatments or in combination with other therapies designed to treat obesity and/or facilitate greater patient control of eating habits.
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
This application is a U.S. National Phase filing of PCT Patent Application No. PCT/IL02/00007, filed Jan. 3, 2002, which is based upon U.S. Provisional Patent Application Ser. No. 60/259,925, filed Jan. 5, 2001, each of which is incorporated herewith by reference.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/IL02/00007 | 1/3/2002 | WO | 00 | 10/14/2003 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO02/053093 | 7/11/2002 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3411507 | Wingrove | Nov 1968 | A |
3516412 | Ackerman | Jun 1970 | A |
3737579 | Bolduc | Jun 1973 | A |
4000745 | Goldberg et al. | Jan 1977 | A |
4010758 | Rockland et al. | Mar 1977 | A |
4133315 | Berman et al. | Jan 1979 | A |
4177818 | De Pedro | Dec 1979 | A |
4235246 | Weiss | Nov 1980 | A |
4280503 | Ackerman | Jul 1981 | A |
4313448 | Stokes | Feb 1982 | A |
4357946 | Dutcher et al. | Nov 1982 | A |
4378023 | Trabucco | Mar 1983 | A |
4416267 | Garren et al. | Nov 1983 | A |
4452254 | Goldberg et al. | Jun 1984 | A |
4485805 | Foster, Jr. | Dec 1984 | A |
4592339 | Kuzmak | Jun 1986 | A |
4823808 | Clegg et al. | Apr 1989 | A |
4975682 | Kerr et al. | Dec 1990 | A |
5074868 | Kuzmak | Dec 1991 | A |
5101814 | Palti | Apr 1992 | A |
5103804 | Abele et al. | Apr 1992 | A |
5105812 | Corman | Apr 1992 | A |
5188104 | Wernicke | Feb 1993 | A |
5226429 | Kuzmak | Jul 1993 | A |
5234454 | Bangs | Aug 1993 | A |
5247938 | Silverstein et al. | Sep 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5368028 | Palti | Nov 1994 | A |
5423872 | Cigaina | Jun 1995 | A |
5449368 | Kuzmak | Sep 1995 | A |
5514175 | Kim et al. | May 1996 | A |
5540730 | Terry et al. | Jul 1996 | A |
5551425 | Essen-Moller | Sep 1996 | A |
5601604 | Vincent | Feb 1997 | A |
5690691 | Chen | Nov 1997 | A |
5704368 | Asano et al. | Jan 1998 | A |
5716385 | Mittal et al. | Feb 1998 | A |
5792210 | Wamubu et al. | Aug 1998 | A |
5795304 | Sun et al. | Aug 1998 | A |
5836994 | Bourgeois | Nov 1998 | A |
5837006 | Ocel et al. | Nov 1998 | A |
5861014 | Familoni | Jan 1999 | A |
5868141 | Ellias | Feb 1999 | A |
5938669 | Klaiber et al. | Aug 1999 | A |
5979449 | Steer | Nov 1999 | A |
5991649 | Garfield et al. | Nov 1999 | A |
5995872 | Bourgeois | Nov 1999 | A |
6026326 | Bardy | Feb 2000 | A |
6041258 | Cigaina et al. | Mar 2000 | A |
6067991 | Forsell | May 2000 | A |
6083249 | Familoni | Jul 2000 | A |
6091992 | Bourgeois | Jul 2000 | A |
6092528 | Edwards | Jul 2000 | A |
6104955 | Bourgeois | Aug 2000 | A |
6115635 | Bourgeois | Sep 2000 | A |
6129685 | Howard | Oct 2000 | A |
6132372 | Essen-Moller | Oct 2000 | A |
6135987 | Tsai et al. | Oct 2000 | A |
6216045 | Black et al. | Apr 2001 | B1 |
6243607 | Mintchev et al. | Jun 2001 | B1 |
6249697 | Asano et al. | Jun 2001 | B1 |
6334073 | Levine | Dec 2001 | B1 |
6363937 | Hovda et al. | Apr 2002 | B1 |
6381495 | Jenkins | Apr 2002 | B1 |
6405732 | Edwards | Jun 2002 | B1 |
6411842 | Cigaina et al. | Jun 2002 | B1 |
6415178 | Ben-Haim et al. | Jul 2002 | B1 |
6427089 | Knowlton | Jul 2002 | B1 |
6449511 | Mintchev et al. | Sep 2002 | B1 |
6454699 | Forsell | Sep 2002 | B1 |
6535764 | Imran et al. | Mar 2003 | B2 |
6571127 | Ben-Haim et al. | May 2003 | B1 |
6572542 | Houben et al. | Jun 2003 | B1 |
6584348 | Glukhovsky | Jun 2003 | B2 |
6591137 | Fischell et al. | Jul 2003 | B1 |
6600953 | Flesler et al. | Jul 2003 | B2 |
6606523 | Jenkins | Aug 2003 | B1 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6612983 | Marchal | Sep 2003 | B1 |
6652444 | Ross | Nov 2003 | B1 |
6658297 | Loeb | Dec 2003 | B2 |
6684104 | Gordon | Jan 2004 | B2 |
6735477 | Levine | May 2004 | B2 |
6745079 | King | Jun 2004 | B2 |
6754536 | Swoyer et al. | Jun 2004 | B2 |
6826428 | Chen et al. | Nov 2004 | B1 |
6832114 | Whitehurst | Dec 2004 | B1 |
6852110 | Roy et al. | Feb 2005 | B2 |
6853862 | Marchal et al. | Feb 2005 | B1 |
6869431 | Maguire et al. | Mar 2005 | B2 |
6876885 | Swoyer et al. | Apr 2005 | B2 |
6895279 | Loeb et al. | May 2005 | B2 |
6918906 | Long | Jul 2005 | B2 |
6939349 | Fleischman et al. | Sep 2005 | B2 |
6947792 | Ben-Haim et al. | Sep 2005 | B2 |
6952613 | Swoyer et al. | Oct 2005 | B2 |
7043295 | Starkebaum | May 2006 | B2 |
7054690 | Imran | May 2006 | B2 |
7076305 | Imran et al. | Jul 2006 | B2 |
7076306 | Marchal et al. | Jul 2006 | B2 |
20010011543 | Forsell | Aug 2001 | A1 |
20020026141 | Houben | Feb 2002 | A1 |
20020103424 | Swoyer et al. | Aug 2002 | A1 |
20030009202 | Levine | Jan 2003 | A1 |
20030045919 | Swoyer et al. | Mar 2003 | A1 |
20030055464 | Darvish | Mar 2003 | A1 |
20030066536 | Forsell | Apr 2003 | A1 |
20030144708 | Starkebaum | Jul 2003 | A1 |
20030195600 | Tronnes et al. | Oct 2003 | A1 |
20030208212 | Cigaina | Nov 2003 | A1 |
20030208242 | Harel et al. | Nov 2003 | A1 |
20030220678 | Tronnes et al. | Nov 2003 | A1 |
20040044376 | Flesler et al. | Mar 2004 | A1 |
20040059393 | Policker et al. | Mar 2004 | A1 |
20040088023 | Imran et al. | May 2004 | A1 |
20040107004 | Levine et al. | Jun 2004 | A1 |
20040147816 | Policker et al. | Jul 2004 | A1 |
20040158138 | Kilcoyne et al. | Aug 2004 | A1 |
20040162469 | Imran | Aug 2004 | A1 |
20040162595 | Foley | Aug 2004 | A1 |
20040167583 | Knudson et al. | Aug 2004 | A1 |
20040193184 | Laufer et al. | Sep 2004 | A1 |
20040236316 | Danitz et al. | Nov 2004 | A1 |
20040249421 | Harel et al. | Dec 2004 | A1 |
20050021101 | Chen et al. | Jan 2005 | A1 |
20050055038 | Kelleher et al. | Mar 2005 | A1 |
20050065505 | Ryan | Mar 2005 | A1 |
20050075654 | Kelleher | Apr 2005 | A1 |
20050090873 | Imran | Apr 2005 | A1 |
20050107829 | Edwards et al. | May 2005 | A1 |
20050143784 | Imran | Jun 2005 | A1 |
20050183732 | Edwards | Aug 2005 | A1 |
20050192615 | Torre et al. | Sep 2005 | A1 |
20050203500 | Saadat et al. | Sep 2005 | A1 |
20050209653 | Herbert et al. | Sep 2005 | A1 |
20050222638 | Foley et al. | Oct 2005 | A1 |
20060142803 | Mintchev | Jun 2006 | A1 |
20060173238 | Starkebaum | Aug 2006 | A1 |
20060247718 | Starkebaum | Nov 2006 | A1 |
EP 1 447 052 | Aug 2004 |
Number | Date | Country |
---|---|---|
0 057 048 | Aug 1982 | EP |
0 129 483 | Dec 1984 | EP |
EP 144705 | Oct 1984 | JP |
2003319945 | Nov 2003 | JP |
WO 9401172 | Jan 1994 | WO |
WO 9725098 | Jul 1997 | WO |
WO 9810830 | Mar 1998 | WO |
WO 9903533 | Jan 1999 | WO |
WO 0141671 | Jun 2001 | WO |
WO 0226101 | Apr 2002 | WO |
WO 02053093 | Jul 2002 | WO |
WO 02082968 | Oct 2002 | WO |
WO 02089655 | Nov 2002 | WO |
WO 03020365 | Mar 2003 | WO |
WO 2004043280 | May 2004 | WO |
WO 2004066903 | Aug 2004 | WO |
WO 2004069330 | Aug 2004 | WO |
WO 2004091361 | Oct 2004 | WO |
WO 2004096337 | Nov 2004 | WO |
WO 2004112563 | Dec 2004 | WO |
WO 2005007232 | Jan 2005 | WO |
WO 2005007237 | Jan 2005 | WO |
WO 2005009288 | Feb 2005 | WO |
WO 2005016181 | Feb 2005 | WO |
WO 2005023081 | Mar 2005 | WO |
WO 2005037152 | Apr 2005 | WO |
WO 2005041749 | May 2005 | WO |
WO 2005087310 | Sep 2005 | WO |
WO 2006035446 | Apr 2006 | WO |
WO 2006118790 | Nov 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20040059393 A1 | Mar 2004 | US |
Number | Date | Country | |
---|---|---|---|
60259925 | Jan 2001 | US |